Controversial treatment of atherosclerotic renal vascular disease: the cardiovascular outcomes in renal atherosclerotic lesions trial.
نویسنده
چکیده
Atherosclerotic renal artery stenosis (RAS) is a relatively common problem, affecting from 1% to 5% of patients with hypertension.1,2 Given the high prevalence of hypertension, it follows that there are from 2 million to 4 million individuals with RAS in the United States alone. Autopsy data demonstrate that the incidence of RAS increases with age affecting 18% of individuals between the ages 65 to 74 years and 40% of those more than age 75.3 RAS is also common in individuals with vascular disease in other beds and is present in 40% of those with overt coronary artery disease, aortoiliac disease, or peripheral vascular disease.4–6 At present, the best treatment for RAS is unknown, and, in particular, whether or not revascularization, typically accomplished by angioplasty and stenting, improves clinical outcomes for patients with RAS is unclear. Nevertheless, it is estimated that 40 000 renal artery angioplasties procedures are performed in the United States each year, which, depending on whether or not the procedure is beneficial, is either far too many or far too few. The purpose of this article is to review current knowledge about atherosclerotic RAS and to discuss the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, which is examining the best treatment for this disease.
منابع مشابه
The Cardiovascular Outcomes in Renal Atherosclerotic Lesions Trial
Atherosclerotic renal artery stenosis (RAS) is a relatively common problem, affecting from 1% to 5% of patients with hypertension.1,2 Given the high prevalence of hypertension, it follows that there are from 2 million to 4 million individuals with RAS in the United States alone. Autopsy data demonstrate that the incidence of RAS increases with age affecting 18% of individuals between the ages 6...
متن کاملManagement of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL).
Many patients with occlusive atherosclerotic renovascular disease (ARVD) may be managed effectively with medical therapy for several years without endovascular stenting, as demonstrated by randomized, prospective trials including the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial and the Stent Placemen...
متن کاملEffect of pyridoxal phosphate on atherosclerosis and nephropathy progression in the atherosclerotic rats
Background and Objectives: Diabetes vascular complications are the principal cause of death in the world. Therefore, we investigated the effect of pyridoxal phosphate (PLP) on the formation of atheromatous plaque formation and renal function in the atherosclerotic rats. Materials and Methods: Male Wistar rats were randomly divided into 4 equal groups (ten rats in each group): normal, ath...
متن کاملRevascularization of Atherosclerotic Renal ArteryStenosis in Selected Patients: Benefits on Kidneyand Cardiac Function
The atherosclerotic renal artery stenosis is mostly diagnosed in the elderly and often coexists with other vascular diseases. It is a progressive disease that can lead to resistant hypertension and progressive loss of functional renal mass. Additionally, it has been associated with ischemic heart disease and increased cardiovascular morbidity and mortality. The treatment of atherosclerotic rena...
متن کاملCurrent management of atherosclerotic renovascular disease--what have we learned from ASTRAL?
With an increasingly ageing and atherosclerotic-prone population, clinical encounters with patients with atheromatous renovascular disease (ARVD) are commonplace. ARVD is frequently associated with chronic kidney disease (CKD) and hypertension, but evidence suggests that causality only occurs in the minority and it is likely that many atherosclerotic renal artery stenosis (RAS) lesions are inci...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hypertension
دوره 48 3 شماره
صفحات -
تاریخ انتشار 2006